- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Tonix Pharmaceuticals Holding Corp(TNXP)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TNXP
11/20/2026: TNXP (1-star) is currently NOT-A-BUY. Pass it for now.
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for central nervous system disorders, rare diseases, and infectious conditions. Its primary investment appeal lies in the late-stage development of its lead candidate, TNX-102 SL, for fibromyalgia, offering potential high-growth upside. However, the company faces significant execution, regulatory, and financing risks common to pre-revenue biotech firms, alongside heavy dilution and intense competition. The stock best suits risk-tolerant investors looking for binary clinical milestones, requiring close monitoring of upcoming FDA decisions and cash runway updates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Offers potential high-growth upside dependent on clinical milestones, but lacks consistent historical revenue growth. |
| Momentum investor | Strong fit while signal remains positive | Can experience sharp short-term price movements surrounding clinical data readouts or regulatory updates. |
| Value investor | Weak fit | Lacks traditional value metrics such as positive earnings, cash flow generation, or book value stability. |
| Dividend investor | Weak fit | The company does not pay dividends and retains all capital for clinical research. |
| Low-risk investor | Weak fit | High clinical, regulatory, and financial dilution risks create substantial share price volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is highly sensitive to clinical trial outcomes, regulatory updates, and market sentiment. |
| Valuation risk | High | Valuation relies heavily on speculative future cash flows from pipeline assets rather than current fundamentals. |
| Competition risk (large pharma dominance) | High | Well-capitalized competitors dominate the therapeutic markets Tonix aims to enter. |
| Business quality | Medium | The company holds promising intellectual property but lacks commercial-stage operations. |
| Dividend income | Low / none | No dividend is paid or expected in the near term. |
| Execution risk | High | Success depends entirely on navigating clinical trials and securing complex regulatory approvals. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 49.55M USD | Price to earnings Ratio - | 1Y Target Price 31.6 |
Price to earnings Ratio - | 1Y Target Price 31.6 | ||
Volume (30-day avg) 1.1M shares | Beta 1.9 | 52 Weeks Range 2.30 - 20.56 | Updated Date 11/20/2026 |
52 Weeks Range 2.30 - 20.56 | Updated Date 11/20/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.39 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Biotechnology
- BUY participation
- 43.2%
- Active BUY / eligible
- 19 / 44
- 30-Day BUY Count Change
- +12
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -42.8% | Avg. Invested days 12 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales & Licensing (Future) | Anticipated future revenue from commercializing proprietary therapeutics like TNX-102 SL and potential milestone or royalty payments from licensing agreements. | Currently, the company generates minimal commercial revenue and relies on equity financing while advancing its drug pipeline toward market readiness. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -111.99M | Price to Sales(TTM) 1.15 |
Enterprise Value -111.99M | Price to Sales(TTM) 1.15 | ||
Enterprise Value to Revenue 0.4 | Enterprise Value to EBITDA 0.94 | Shares Outstanding 19.43M | Shares Floating 18.27M |
Shares Outstanding 19.43M | Shares Floating 18.27M | ||
Percent Insiders 0.17 | Percent Institutions 53.21 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

